Description of the medicine: Etamide (Aethamidum)
ETAMID (Aethamidum). 4-N, N-diethylamide of para-sulfobenzoic acid.
White crystalline powder; odorless and tasteless. It is practically insoluble in water, easily in solutions of caustic and carbonic alkalis.
The drug inhibits the reabsorption of uric acid in the renal tubules, promotes its excretion in the urine and a decrease in blood levels.
Ethamide is used for gout and other conditions, accompanied by the accumulation of uric acid in the body (polyarthritis with impaired purine metabolism, kidney stone disease with the formation of urates). In acute attacks of gout, the drug is ineffective, it does not have an analgesic effect.
The drug is also used for torpid forms of herpetiform dermatitis (Dühring’s disease).
Ethamide is prescribed to adults inside after eating 0.35 g 4 times a day for 10 to 12 days. After a 5 - 7-day break, a second course is carried out lasting 7 days.
With Dühring’s disease, 0.35 g is prescribed 3-4 times a day in combination with diaphenylsulfone (see) in 2-week cycles with 5-7-day breaks; only 2 to 3 cycles.
Etamide is generally well tolerated. In some cases, dyspeptic and dysuric phenomena are possible, passing on their own. When treating with etamide, it is necessary to monitor renal function.
The drug has the ability to delay the release of penicillin and other drugs by the kidneys.
Contraindications: severe liver and kidney disease.
Release form: tablets on 0,35 g.
Storage: List B. In a dry place.